All the news Showing 2 of 12 articles from: Experimental treatments for NASH/NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Emricasan and selonsertib fail to improve fibrosis in people with NASH Liz Highleyman / 12 November 2019 A pair of experimental therapies for non-alcoholic steatohepatitis (NASH) failed to offer notable improvements in controlled clinical trials, despite having shown promising effects on liver biomarkers in earlier studies. Dr Stephen Harrison ... Tesamorelin reduces liver fat and fibrosis progression in people with HIV and NAFLD Keith Alcorn / 21 October 2019 Treatment with tesamorelin, a synthetic growth hormone-releasing hormone, reduced liver fat content and reduced the progression of liver fibrosis in people with HIV who had non-alcoholic fatty liver disease (NAFLD), researchers report ... ← Prev12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive